2024

  1. Natural History of Nonmetastatic Prostate Cancer Managed With Watchful Waiting. Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H.JAMA Netw Open. 2024 Jun Sammanfattning Fulltext
  2. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study, Pietro Scilipoti, Fredrik Liedberg, Hans Garmo, Andri Wilberg Orrason, Pär Stattin, Marcus Westerberg, Scand J Urol. 2024 May Sammanfattning Fulltext
  3. Mortality Risks Associated with Depression in Men with Prostate Cancer. Crump C, Stattin P, Brooks JD, Sundquist J, Sieh W, Sundquist K.Eur Urol Oncol. 2024 Apr Sammanfattning Fulltext
  4. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study, Lars Egevad, Chiara Micoli, Brett Delahunt, Hemamali Samaratunga, Andri Wilberg Orrason, Hans Garmo, Pär Stattin, Martin Eklund, Virchows Arch. 2024 April Sammanfattning Fulltext
  5. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer, Frederik F Thomsen, Hans Garmo, Lars Egevad, Pär Stattin, Klaus Brasso, Scand J Urol, 2024 Apr Sammanfattning Fulltext
  6. Prostatacancerregistret – för patienter, sjukvård och forskning,Ingela Franck Lissbrant, Johan Styrke, Magnus Törnblom, Marie Hjelm Eriksson, Elin Axén, Pär Stattin, Läkartidningen, 2024 April Fulltext
  7. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, Pai H, Gifkins D, Robinson D, Styrke J, Garmo H. BJU Int. 2024 Apr. Sammafattning Fulltext
  8. Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial. Astrid E Persson EK, Hans Garmo, Gabriel Adrian, Pär Stattin, Anders Widmark, Per, Nilsson AG.  Abstract, ESTRO 2024. Länk till abstract
  9. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 – a case-control study. Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, Bill-Axelson A. Scand J Urol. 2024 Mar. Sammanfattning Fulltext
  10. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, Stattin P, Bratt O.  Int J Cancer. 2024 Mar. Sammanfattning Fulltext
  11. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Acta Oncol. 2024 Mar. Sammanfattning Fulltext.
  12. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, Nagel G, Zitt E, Engeland A, Harlid S, Drake I, Stattin P, Stocks T.  Br J Cancer. 2024 Feb. Sammanfattning Fulltext
  13. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study. Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. PLoS One. 2024 Jan. Sammanfattning Fulltext
  14. Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study. Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, Kindblom J, Robinson D, Westerberg M, Stattin P, Carlsson SV. Eur Urol Oncol. 2024 Jan. Sammanfattning Fulltext